Antonella Cammarota

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study

Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida et al. · Hepatology · 2022 · 234 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +11

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D’Alessio et al. · European Journal of Cancer · 2022 · 112 citations · Full text

Medicine, Oncology, Pharmacology +6

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Linda Y. Wu, Claudia Angela Maria Fulgenzi, Antonio D’Alessio et al. · Cancers · 2022 · 70 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

Bernhard Scheiner, Daniel Roessler, Samuel Phen et al. · JHEP Reports · 2022 · 61 citations · Full text

Medicine, Immunology, Oncology +14

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Mathew Vithayathil, Antonio D’Alessio, Claudia Angela Maria Fulgenzi et al. · Liver International · 2022 · 38 citations · Full text

Medicine, Oncology, Pharmacotherapy +15